EasySep™小鼠TIL（CD45）正选试剂盒
Scientific Resources
-
Innate Lymphoid Cells Overview of innate lymphoid cells (ILCs) development, classification, plasticity and functional diversity -
How EasySep™ Magnetic Cell Separation Technology Works: Fast and Easy Cell Isolation EasySep™ technology, a fast and easy immunomagnetic cell separation technology that allows you to isolate virtually any cell types from a variety of sample sources in as little as 8 minutes -
BrainPhys™: A New Way to Culture Neurons BrainPhys™ takes your neuronal culture system one step closer to the brain environment -
SnapShot: The Intestinal Crypt Overview of the intestinal stem cell niche, major cell types and signaling pathways -
Non-Viral CRISPR Knock-In Anti-B7-H3 CAR-T Cells Are Amenable for Treatment of Subtypes of Small Cell Lung Cancer In this webinar, Scientist Vimal Keerthi discusses his work on identifying CD276 (B7-H3) overexpression in primary human SCLC and developing a non-viral CRISPR-Cas9 knock-in (CKI) based platform against B7-H3 to manufacture CAR T cells for the treatment of SCLC. He demonstrates the feasibility of this CAR T manufacturing platform and how this provides a blueprint for immediate clinical translation, overcoming the bottleneck of viral vector production.
This webinar is part of the “Translational T Cell Talks: Scaling for the Future” event hosted in collaboration with Scientist.com on June 11, 2024. View the rest of the talks and read the Q&A transcripts.
